Saturday 17 October 2026
Export EMBC’s income statement to Excel — free account
Embecta Corp.
EMBC Healthcare Medical Instruments & Supplies
Embecta Corp.’s revenue for fiscal 2025 (year ended September 2025) was $1.1 billion, down 3.80% from fiscal 2024. In the quarter to June 2026, revenue fell 8.05%, EPS fell 53.9%, free cash flow fell 49.6% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.27
0.18
−2.79%
Follow EMBC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
2.19 | 4.63 | 4.99 | 8.66 |
+8 more quarters Free account |
P/S ratio |
0.19 | 0.50 | 0.65 | 0.76 | |
P/FCF ratio |
1.09 | 2.44 | 3.24 | 4.51 | |
P/Operating CF |
4.56 | 16.86 | 40.61 | 9.79 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.43 | 1.62 | 1.75 | 1.87 | |
EV/EBITDA |
5.06 | 5.09 | 5.27 | 6.69 | |
EV/Operating CF |
8.36 | 7.89 | 8.80 | 10.54 | |
EV/FCF |
8.33 | 7.84 | 8.73 | 11.08 | |
Quick Ratio |
0.95 | 1.38 | 1.55 | 1.43 | |
Current Ratio |
1.68 | 2.46 | 2.64 | 2.41 | |
Net Debt/EBITDA |
19.39 | 23.36 | 12.09 | 16.02 | |
Debt/Assets |
117.17% | 131.57% | 130.73% | 130.80% | |
Debt/Equity |
(2.42) | (2.16) | (2.27) | (2.19) | |
Asset Turnover |
0.84 | 0.97 | 0.98 | 0.91 | |
Operating CF/Net income |
1.98 | (7.59) | 0.39 | 3.18 | |
Capex/Depreciation |
(0.07) | (0.03) | 0.64 | (0.40) | |
Interest Coverage |
2.04 | 1.55 | 3.46 | 2.16 | |
Research and Development Expense of Revenue |
2.06% | 2.43% | 1.76% | 1.74% | |
Selling, General and Administrative Expense of Revenue |
28.93% | 34.36% | 29.71% | 32.92% | |
Intangible Assets out of Total Assets |
0.07 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
1.55% | 2.57% | 2.26% | 3.60% | |
Graham Net Nets |
(6.15) | (2.00) | (1.51) | (1.35) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
45.71% | 21.61% | 20.03% | 11.55% | |
Free Cash Flow Yield |
91.64% | 40.98% | 30.91% | 22.17% | |
Revenue per Share |
4.65 | 3.74 | 4.44 | 4.53 | |
Operating CF per Share |
0.71 | 0.52 | 0.29 | 1.44 | |
Capex per Share |
(0.02) | (0.01) | 0.16 | (0.13) | |
Free Cash Flow per Share |
0.70 | 0.52 | 0.45 | 1.32 | |
Cash per Share |
3.73 | 3.26 | 3.48 | 3.92 | |
Shareholders Equity per Share |
(10.48) | (10.56) | (10.43) | (11.16) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(10.48) | (10.56) | (10.43) | (11.16) | |
Free Cash Flow |
40.70 | 30.60 | 26.70 | 76.70 | |
Working Capital |
285.30 | 360.80 | 385.50 | 369.90 | |
Capital Expenditures |
(1.10) | (0.50) | 9.50 | (7.30) | |
Net Current Asset Value |
(1,172.90) | (1,047.30) | (1,056.60) | (1,110.10) | |
EV/EBIT |
6.51 | 6.27 | 6.35 | 8.35 | |
Capex to Sales |
0.00 | 0.00 | (0.04) | 0.03 | |
Price to Operating Income |
0.85 | 1.95 | 2.35 | 3.40 | |
| Other line items | |||||
Average Receivables |
182.50 | 166.35 | 170.05 | 169.30 | |
Average Payables |
76.20 | 69.25 | 72.55 | 82.60 | |
Average Inventory |
202.05 | 180.90 | 175.45 | 175.05 | |
Average Assets |
1,211.30 | 1,074.75 | 1,106.60 | 1,188.10 | |
Average Common Equity |
(641.15) | (681.15) | (690.95) | (694.45) |
Columns are period end dates